Charles Bennett to Ovarian Neoplasms
This is a "connection" page, showing publications Charles Bennett has written about Ovarian Neoplasms.
Connection Strength
0.776
-
A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol. 2004 Apr; 93(1):164-9.
Score: 0.196
-
Pharmacoeconomics of amifostine in ovarian cancer. Semin Oncol. 1999 Apr; 26(2 Suppl 7):102-7.
Score: 0.138
-
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 1):40-5.
Score: 0.137
-
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients. Cancer Invest. 1999; 17(8):559-65.
Score: 0.136
-
Pharmacoeconomics of liposomal anthracycline therapy. Semin Oncol. 2004 Dec; 31(6 Suppl 13):191-5.
Score: 0.051
-
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med. 2004 Jan 01; 116(1):28-34.
Score: 0.048
-
Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial. Cancer Invest. 2000; 18(3):261-8.
Score: 0.036
-
Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecol Oncol. 1998 Dec; 71(3):369-75.
Score: 0.034